These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36497248)

  • 21. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
    Tio M; Wang X; Carlino MS; Shivalingam B; Fogarty GB; Guminski AD; Lo S; Hong AM; Menzies AM; Long GV
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):509-515. PubMed ID: 29277979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival in melanoma brain metastases in the era of novel systemic therapies.
    Merola JP; Ocen J; Kumar S; Powell J; Hayhurst C
    Neurooncol Adv; 2020; 2(1):vdaa144. PubMed ID: 33392503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review.
    van Opijnen MP; Dirven L; Coremans IEM; Taphoorn MJB; Kapiteijn EHW
    Int J Cancer; 2020 Mar; 146(6):1479-1489. PubMed ID: 31583684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis.
    Zubatkina I; Ivanov P
    J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
    Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
    Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
    J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
    Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.
    Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    J Clin Oncol; 2012 Feb; 30(4):419-25. PubMed ID: 22203767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
    Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
    Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation and discussion of clinical practicability of the 2022 graded prognostic assessment for NSCLC adenocarcinoma patients with brain metastases in a routine clinical cohort.
    Schröder C; Windisch P; Lütscher J; Zwahlen DR; Förster R
    Front Oncol; 2023; 13():1042548. PubMed ID: 37020868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.
    Sperduto PW; Chao ST; Sneed PK; Luo X; Suh J; Roberge D; Bhatt A; Jensen AW; Brown PD; Shih H; Kirkpatrick J; Schwer A; Gaspar LE; Fiveash JB; Chiang V; Knisely J; Sperduto CM; Mehta M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):655-61. PubMed ID: 19942357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
    Chowdhury IH; Ojerholm E; McMillan MT; Miller D; Kolker JD; Kurtz G; Dorsey JF; Nagda SN; Geiger GA; Brem S; O'Rourke DM; Zager EL; Gangadhar T; Schuchter L; Lee JY; Alonso-Basanta M
    Radiat Oncol; 2015 Dec; 10():248. PubMed ID: 26626714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
    Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort.
    Dalmasso C; Pagès C; Chaltiel L; Brun A; Sibaud V; Boulinguez S; Chira C; Moyal E; Lubrano V; Meyer N; Modesto A
    Melanoma Res; 2020 Oct; 30(5):472-476. PubMed ID: 32404732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.